BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jin UH, Lee SO, Pfent C, Safe S. The aryl hydrocarbon receptor ligand omeprazole inhibits breast cancer cell invasion and metastasis. BMC Cancer 2014;14:498. [PMID: 25011475 DOI: 10.1186/1471-2407-14-498] [Cited by in Crossref: 86] [Cited by in F6Publishing: 91] [Article Influence: 10.8] [Reference Citation Analysis]
Number Citing Articles
1 Safe S, Zhang L. The Role of the Aryl Hydrocarbon Receptor (AhR) and Its Ligands in Breast Cancer. Cancers 2022;14:5574. [DOI: 10.3390/cancers14225574] [Reference Citation Analysis]
2 Yamashita N, Kawai K, Yoshikawa M, Watabe M, Kanno Y, Sanada N, Kizu R. FDI-6, a FOXM1 inhibitor, activates the aryl hydrocarbon receptor and suppresses tumorsphere formation. Biochemical and Biophysical Research Communications 2022. [DOI: 10.1016/j.bbrc.2022.11.069] [Reference Citation Analysis]
3 Giuliani A, Fais S. Proposal to Consider Chemical/Physical Microenvironment as a New Therapeutic Off-Target Approach. Pharmaceutics 2022;14:2084. [DOI: 10.3390/pharmaceutics14102084] [Reference Citation Analysis]
4 Ballinger TJ, Djuric Z, Sardesai S, Hovey KM, Andrews CA, Brasky TM, Zhang JT, Rohan TE, Saquib N, Shadyab AH, Simon M, Wactawski-wende J, Wallace R, Kato I. Proton Pump Inhibitor Use and Obesity-Associated Cancer in the Women’s Health Initiative. Nutrition and Cancer. [DOI: 10.1080/01635581.2022.2108467] [Reference Citation Analysis]
5 Xu T, Luo Y, Xie HQ, Xia Y, Li Y, Chen Y, Guo Z, Xu L, Zhao B. Systematic identification of molecular mechanisms for aryl hydrocarbon receptor mediated neuroblastoma cell migration. Environ Int 2022;168:107461. [PMID: 35981476 DOI: 10.1016/j.envint.2022.107461] [Reference Citation Analysis]
6 Tan Q, Cai J, Peng J, Hu C, Wu C, Liu H. VEGF-B targeting by aryl hydrocarbon receptor mediates the migration and invasion of choriocarcinoma stem-like cells. Cancer Cell Int 2022;22:221. [PMID: 35773697 DOI: 10.1186/s12935-022-02641-8] [Reference Citation Analysis]
7 Tian X, Zheng S, Wang J, Yu M, Lin Z, Qin M, Wu Y, Chen S, Zhong S. Cardiac disorder-related adverse events for aryl hydrocarbon receptor agonists: a safety review. Expert Opin Drug Saf 2022. [PMID: 35582860 DOI: 10.1080/14740338.2022.2078301] [Reference Citation Analysis]
8 Heneberg P. Lactic Acidosis in Patients with Solid Cancer. Antioxid Redox Signal 2022. [PMID: 35316087 DOI: 10.1089/ars.2021.0267] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Xu L, Liu Y, Chen Y, Zhu R, Li S, Zhang S, Zhang J, Xie HQ, Zhao B. Emodin inhibits U87 glioblastoma cells migration by activating aryl hydrocarbon receptor (AhR) signaling pathway. Ecotoxicol Environ Saf 2022;234:113357. [PMID: 35272197 DOI: 10.1016/j.ecoenv.2022.113357] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Liu J, Pi Z, Xiao Y, Zeng Z, Yu J, Zou P, Tang B, Qiu X, Tang R, Shi Y, Xiao R. Esomeprazole alleviates fibrosis in systemic sclerosis by modulating AhR/Smad2/3 signaling. Pharmacol Res 2022;176:106057. [PMID: 34995795 DOI: 10.1016/j.phrs.2022.106057] [Reference Citation Analysis]
11 Liu Z, Ren Z, Zhang C, Qian R, Wang H, Wang J, Zhang W, Liu B, Lian X, Wang Y, Guo Y, Gao Y. ELK3: A New Molecular Marker for the Diagnosis and Prognosis of Glioma. Front Oncol 2021;11:608748. [PMID: 34976781 DOI: 10.3389/fonc.2021.608748] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Li Y, Ren BX, Li HM, Lu T, Fu R, Wu ZQ. Omeprazole suppresses aggressive cancer growth and metastasis in mice through promoting Snail degradation. Acta Pharmacol Sin 2021. [PMID: 34785782 DOI: 10.1038/s41401-021-00787-1] [Reference Citation Analysis]
13 Hanieh H, Ibrahim HM, Mohammed M, Alwassil OI, Abukhalil MH, Farhan M. Activation of aryl hydrocarbon receptor signaling by gallic acid suppresses progression of human breast cancer in vitro and in vivo. Phytomedicine 2021;:153817. [PMID: 34782204 DOI: 10.1016/j.phymed.2021.153817] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 Panitz V, Končarević S, Sadik A, Friedel D, Bausbacher T, Trump S, Farztdinov V, Schulz S, Sievers P, Schmidt S, Jürgenson I, Jung S, Kuhn K, Pflüger I, Sharma S, Wick A, Pfänder P, Selzer S, Vollmuth P, Sahm F, von Deimling A, Heiland I, Hopf C, Schulz-Knappe P, Pike I, Platten M, Wick W, Opitz CA. Tryptophan metabolism is inversely regulated in the tumor and blood of patients with glioblastoma. Theranostics 2021;11:9217-33. [PMID: 34646367 DOI: 10.7150/thno.60679] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
15 Kamiya C, Odagiri K, Hakamata A, Sakurada R, Inui N, Watanabe H. Omeprazole suppresses endothelial calcium response and eNOS Ser1177 phosphorylation in porcine aortic endothelial cells. Mol Biol Rep 2021;48:5503-11. [PMID: 34291395 DOI: 10.1007/s11033-021-06561-0] [Reference Citation Analysis]
16 Hipólito A, Martins F, Mendes C, Lopes-Coelho F, Serpa J. Molecular and Metabolic Reprogramming: Pulling the Strings Toward Tumor Metastasis. Front Oncol 2021;11:656851. [PMID: 34150624 DOI: 10.3389/fonc.2021.656851] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
17 Liu Y, Chen Y, Sha R, Li Y, Xu T, Hu X, Xu L, Xie Q, Zhao B. A new insight into the role of aryl hydrocarbon receptor (AhR) in the migration of glioblastoma by AhR-IL24 axis regulation. Environ Int 2021;154:106658. [PMID: 34082239 DOI: 10.1016/j.envint.2021.106658] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
18 Liao M, Zhang J, Wang G, Wang L, Liu J, Ouyang L, Liu B. Small-Molecule Drug Discovery in Triple Negative Breast Cancer: Current Situation and Future Directions. J Med Chem 2021;64:2382-418. [PMID: 33650861 DOI: 10.1021/acs.jmedchem.0c01180] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 25.0] [Reference Citation Analysis]
19 Lu P, Yamaguchi Y, Fulton WB, Wang S, Zhou Q, Jia H, Kovler ML, Salazar AG, Sampah M, Prindle T Jr, Wipf P, Sodhi CP, Hackam DJ. Maternal aryl hydrocarbon receptor activation protects newborns against necrotizing enterocolitis. Nat Commun 2021;12:1042. [PMID: 33589625 DOI: 10.1038/s41467-021-21356-4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 19] [Article Influence: 13.0] [Reference Citation Analysis]
20 Szelest M, Walczak K, Plech T. A New Insight into the Potential Role of Tryptophan-Derived AhR Ligands in Skin Physiological and Pathological Processes. Int J Mol Sci 2021;22:1104. [PMID: 33499346 DOI: 10.3390/ijms22031104] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 19.0] [Reference Citation Analysis]
21 Nocentini A, Fais S. Proton pump inhibitors and other pH-buffering agents. pH-Interfering Agents as Chemosensitizers in Cancer Therapy 2021. [DOI: 10.1016/b978-0-12-820701-7.00011-7] [Reference Citation Analysis]
22 Wang Z, Snyder M, Kenison JE, Yang K, Lara B, Lydell E, Bennani K, Novikov O, Federico A, Monti S, Sherr DH. How the AHR Became Important in Cancer: The Role of Chronically Active AHR in Cancer Aggression. Int J Mol Sci 2020;22:E387. [PMID: 33396563 DOI: 10.3390/ijms22010387] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 10.0] [Reference Citation Analysis]
23 Mukha A, Dubrovska A. Metabolic Targeting of Cancer Stem Cells. Front Oncol. 2020;10:537930. [PMID: 33415069 DOI: 10.3389/fonc.2020.537930] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
24 Nothdurft S, Thumser-Henner C, Breitenbücher F, Okimoto RA, Dorsch M, Opitz CA, Sadik A, Esser C, Hölzel M, Asthana S, Forster J, Beisser D, Kalmbach S, Grüner BM, Bivona TG, Schramm A, Schuler M. Functional screening identifies aryl hydrocarbon receptor as suppressor of lung cancer metastasis. Oncogenesis 2020;9:102. [PMID: 33214553 DOI: 10.1038/s41389-020-00286-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
25 Zhao L, Shu Q, Sun H, Ma Y, Kang D, Zhao Y, Lu J, Gong P, Yang F, Wan F. 1'H-Indole-3'-Carbonyl-Thiazole-4-Carboxylic Acid Methyl Ester Blocked Human Glioma Cell Invasion via Aryl Hydrocarbon Receptor's Regulation of Cytoskeletal Contraction. Biomed Res Int 2020;2020:2616930. [PMID: 33083460 DOI: 10.1155/2020/2616930] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
26 Wei Q, Qian Y, Yu J, Wong CC. Metabolic rewiring in the promotion of cancer metastasis: mechanisms and therapeutic implications. Oncogene. 2020;39:6139-6156. [PMID: 32839493 DOI: 10.1038/s41388-020-01432-7] [Cited by in Crossref: 60] [Cited by in F6Publishing: 61] [Article Influence: 30.0] [Reference Citation Analysis]
27 Huybrechts I, Zouiouich S, Loobuyck A, Vandenbulcke Z, Vogtmann E, Pisanu S, Iguacel I, Scalbert A, Indave I, Smelov V, Gunter MJ, Michels N. The Human Microbiome in Relation to Cancer Risk: A Systematic Review of Epidemiologic Studies. Cancer Epidemiol Biomarkers Prev 2020;29:1856-68. [PMID: 32727720 DOI: 10.1158/1055-9965.EPI-20-0288] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 10.5] [Reference Citation Analysis]
28 Jin UH, Michelhaugh SK, Polin LA, Shrestha R, Mittal S, Safe S. Omeprazole Inhibits Glioblastoma Cell Invasion and Tumor Growth. Cancers (Basel) 2020;12:E2097. [PMID: 32731514 DOI: 10.3390/cancers12082097] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
29 Che X, Dai W. Aryl Hydrocarbon Receptor: Its Regulation and Roles in Transformation and Tumorigenesis. Curr Drug Targets 2019;20:625-34. [PMID: 30411679 DOI: 10.2174/1389450120666181109092225] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
30 Costa B, Amorim I, Gärtner F, Vale N. Understanding Breast cancer: from conventional therapies to repurposed drugs. Eur J Pharm Sci 2020;151:105401. [PMID: 32504806 DOI: 10.1016/j.ejps.2020.105401] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
31 Ihraiz WG, Ahram M, Bardaweel SK. Proton pump inhibitors enhance chemosensitivity, promote apoptosis, and suppress migration of breast cancer cells. Acta Pharm 2020;70:179-90. [PMID: 31955147 DOI: 10.2478/acph-2020-0020] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 7.0] [Reference Citation Analysis]
32 Ong TT, Ang Z, Verma R, Koean R, Tam JKC, Ding JL. pHLuc, a Ratiometric Luminescent Reporter for in vivo Monitoring of Tumor Acidosis. Front Bioeng Biotechnol 2020;8:412. [PMID: 32457886 DOI: 10.3389/fbioe.2020.00412] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
33 Paz MFCJ, de Alencar MVOB, de Lima RMP, Sobral ALP, do Nascimento GTM, Dos Reis CA, Coêlho MDPSS, do Nascimento MLLB, Gomes Júnior AL, Machado KDC, de Menezes APM, de Lima RMT, de Oliveira Filho JWG, Dias ACS, Dos Reis AC, da Mata AMOF, Machado SA, Sousa CDC, da Silva FCC, Islam MT, de Castro E Sousa JM, Melo Cavalcante AAC. Pharmacological Effects and Toxicogenetic Impacts of Omeprazole: Genomic Instability and Cancer. Oxid Med Cell Longev 2020;2020:3457890. [PMID: 32308801 DOI: 10.1155/2020/3457890] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
34 Abdulla A, Wang B, Qian F, Kee T, Blasiak A, Ong YH, Hooi L, Parekh F, Soriano R, Olinger GG, Keppo J, Hardesty CL, Chow EK, Ho D, Ding X. Project IDentif.AI: Harnessing Artificial Intelligence to Rapidly Optimize Combination Therapy Development for Infectious Disease Intervention. Adv Ther (Weinh) 2020;:2000034. [PMID: 32838027 DOI: 10.1002/adtp.202000034] [Cited by in Crossref: 24] [Cited by in F6Publishing: 28] [Article Influence: 12.0] [Reference Citation Analysis]
35 Ward C, Meehan J, Gray ME, Murray AF, Argyle DJ, Kunkler IH, Langdon SP. The impact of tumour pH on cancer progression: strategies for clinical intervention. Exploration of Targeted Anti-tumor Therapy 2020;1:71-100. [DOI: 10.37349/etat.2020.00005] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 15.0] [Reference Citation Analysis]
36 Pham TH, Lecomte S, Le Guevel R, Lardenois A, Evrard B, Chalmel F, Ferriere F, Balaguer P, Efstathiou T, Pakdel F. Characterization of Glyceollins as Novel Aryl Hydrocarbon Receptor Ligands and Their Role in Cell Migration. Int J Mol Sci 2020;21:E1368. [PMID: 32085612 DOI: 10.3390/ijms21041368] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
37 Zhao L, Shu Q, Sun H, Ma Y, Kang D, Zhao Y, Lu J, Gong P, Yang F, Wan F. Targeting Aryl Hydrocarbon Receptor with small molecule, 1′H-indole-3′-carbonyl-thiazole-4-carboxylic acid methyl ester blocked human glioma cell invasion via MYH9.. [DOI: 10.1101/2020.01.13.903674] [Reference Citation Analysis]
38 Koltai T, Reshkin SJ, Harguindey S. The vacuolar H+ ATPase proton pump. An Innovative Approach to Understanding and Treating Cancer: Targeting pH 2020. [DOI: 10.1016/b978-0-12-819059-3.00008-3] [Reference Citation Analysis]
39 Dolciami D, Ballarotto M, Gargaro M, López-Cara LC, Fallarino F, Macchiarulo A. Targeting Aryl hydrocarbon receptor for next-generation immunotherapies: Selective modulators (SAhRMs) versus rapidly metabolized ligands (RMAhRLs). Eur J Med Chem 2020;185:111842. [PMID: 31727470 DOI: 10.1016/j.ejmech.2019.111842] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 8.0] [Reference Citation Analysis]
40 Lu ZN, Shi ZY, Dang YF, Cheng YN, Guan YH, Hao ZJ, Tian B, He HW, Guo XL. Pantoprazole pretreatment elevates sensitivity to vincristine in drug-resistant oral epidermoid carcinoma in vitro and in vivo. Biomed Pharmacother 2019;120:109478. [PMID: 31568987 DOI: 10.1016/j.biopha.2019.109478] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
41 Hammond CL, Roztocil E, Phipps RP, Feldon SE, Woeller CF. Proton pump inhibitors attenuate myofibroblast formation associated with thyroid eye disease through the aryl hydrocarbon receptor. PLoS One 2019;14:e0222779. [PMID: 31536596 DOI: 10.1371/journal.pone.0222779] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
42 Yang T, Feng YL, Chen L, Vaziri ND, Zhao YY. Dietary natural flavonoids treating cancer by targeting aryl hydrocarbon receptor. Crit Rev Toxicol 2019;49:445-60. [PMID: 31433724 DOI: 10.1080/10408444.2019.1635987] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 10.0] [Reference Citation Analysis]
43 Jin UH, Karki K, Kim SB, Safe S. Inhibition of pancreatic cancer Panc1 cell migration by omeprazole is dependent on aryl hydrocarbon receptor activation of JNK. Biochem Biophys Res Commun 2018;501:751-7. [PMID: 29758193 DOI: 10.1016/j.bbrc.2018.05.061] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
44 Vorontsova JE, Cherezov RO, Kuzin BA, Simonova OB. Aryl-Hydrocarbon Receptor as a Potential Target for Anticancer Therapy. Biochem Moscow Suppl Ser B 2019;13:36-54. [DOI: 10.1134/s1990750819010116] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
45 Bian Y, Li Y, Shrestha G, Wen X, Cai B, Wang K, Wan X. ITE, an endogenous aryl hydrocarbon receptor ligand, suppresses endometrial cancer cell proliferation and migration. Toxicology 2019;421:1-8. [PMID: 30953668 DOI: 10.1016/j.tox.2019.03.017] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
46 Thews O, Riemann A. Tumor pH and metastasis: a malignant process beyond hypoxia. Cancer Metastasis Rev 2019;38:113-29. [DOI: 10.1007/s10555-018-09777-y] [Cited by in Crossref: 73] [Cited by in F6Publishing: 77] [Article Influence: 24.3] [Reference Citation Analysis]
47 Rowland LK, Campbell PS, Mavingire N, Wooten JV, McLean L, Zylstra D, Thorne G, Daly D, Boyle K, Whang S, Unternaehrer J, Brantley EJ. Putative tumor suppressor cytoglobin promotes aryl hydrocarbon receptor ligand-mediated triple negative breast cancer cell death. J Cell Biochem 2019;120:6004-14. [PMID: 30450577 DOI: 10.1002/jcb.27887] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
48 Zhou D, Jiang C, Fu C, Chang P, Yang B, Wu J, Zhao X, Ma S. Antiproliferative effect of 2-Hydroxy-6-tridecylbenzoic acid from ginkgo biloba sarcotestas through the aryl hydrocarbon receptor pathway in triple-negative breast cancer cells. Nat Prod Res 2020;34:893-7. [PMID: 30445863 DOI: 10.1080/14786419.2018.1508144] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
49 Zgheib E, Limonciel A, Jiang X, Wilmes A, Wink S, van de Water B, Kopp-Schneider A, Bois FY, Jennings P. Investigation of Nrf2, AhR and ATF4 Activation in Toxicogenomic Databases. Front Genet 2018;9:429. [PMID: 30333853 DOI: 10.3389/fgene.2018.00429] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
50 Tripathi SC, Fahrmann JF, Vykoukal JV, Dennison JB, Hanash SM. Targeting metabolic vulnerabilities of cancer: Small molecule inhibitors in clinic. Cancer Rep (Hoboken) 2019;2:e1131. [PMID: 32721114 DOI: 10.1002/cnr2.1131] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
51 Campbell PS, Mavingire N, Khan S, Rowland LK, Wooten JV, Opoku-Agyeman A, Guevara A, Soto U, Cavalli F, Loaiza-Pérez AI, Nagaraj G, Denham LJ, Adeoye O, Jenkins BD, Davis MB, Schiff R, Brantley EJ. AhR ligand aminoflavone suppresses α6-integrin-Src-Akt signaling to attenuate tamoxifen resistance in breast cancer cells. J Cell Physiol 2018;234:108-21. [PMID: 30076704 DOI: 10.1002/jcp.27013] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
52 Vallard A, Rancoule C, Espenel S, Garcia MA, Langrand-Escure J, He MY, Ben Mrad M, El Meddeb Hamrouni A, Ouni S, Trone JC, Rehailia-Blanchard A, Guillaume E, Vial N, Riocreux C, Guy JB, Magné N. Harnessing drug/radiation interaction through daily routine practice: Leverage medical and methodological point of view (MORSE 02-17 study). Radiother Oncol 2018;129:471-8. [PMID: 29937210 DOI: 10.1016/j.radonc.2018.06.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
53 Mahiout S, Tagliabue SG, Nasri A, Omoruyi IM, Pettersson L, Bonati L, Pohjanvirta R. In vitro toxicity and in silico docking analysis of two novel selective AH-receptor modulators. Toxicol In Vitro 2018;52:178-88. [PMID: 29908305 DOI: 10.1016/j.tiv.2018.06.010] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
54 Narasimhan S, Stanford Zulick E, Novikov O, Parks AJ, Schlezinger JJ, Wang Z, Laroche F, Feng H, Mulas F, Monti S, Sherr DH. Towards Resolving the Pro- and Anti-Tumor Effects of the Aryl Hydrocarbon Receptor. Int J Mol Sci 2018;19:E1388. [PMID: 29735912 DOI: 10.3390/ijms19051388] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 7.3] [Reference Citation Analysis]
55 Sundararaghavan VL, Sindhwani P, Hinds TD Jr. Glucuronidation and UGT isozymes in bladder: new targets for the treatment of uroepithelial carcinomas? Oncotarget 2017;8:3640-8. [PMID: 27690298 DOI: 10.18632/oncotarget.12277] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 5.8] [Reference Citation Analysis]
56 Choudhary M, Safe S, Malek G. Suppression of aberrant choroidal neovascularization through activation of the aryl hydrocarbon receptor. Biochim Biophys Acta Mol Basis Dis 2018;1864:1583-95. [PMID: 29481912 DOI: 10.1016/j.bbadis.2018.02.015] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
57 Vacher S, Castagnet P, Chemlali W, Lallemand F, Meseure D, Pocard M, Bieche I, Perrot-Applanat M. High AHR expression in breast tumors correlates with expression of genes from several signaling pathways namely inflammation and endogenous tryptophan metabolism. PLoS One 2018;13:e0190619. [PMID: 29320557 DOI: 10.1371/journal.pone.0190619] [Cited by in Crossref: 48] [Cited by in F6Publishing: 51] [Article Influence: 12.0] [Reference Citation Analysis]
58 Iessi E, Logozzi M, Mizzoni D, Di Raimo R, Supuran CT, Fais S. Rethinking the Combination of Proton Exchanger Inhibitors in Cancer Therapy. Metabolites 2017;8:E2. [PMID: 29295495 DOI: 10.3390/metabo8010002] [Cited by in Crossref: 35] [Cited by in F6Publishing: 42] [Article Influence: 7.0] [Reference Citation Analysis]
59 Safe S. Carbidopa: a selective Ah receptor modulator (SAhRM). Biochem J 2017;474:3763-5. [PMID: 29109131 DOI: 10.1042/BCJ20170728] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
60 Ogura J, Miyauchi S, Shimono K, Yang S, Gonchigar S, Ganapathy V, Bhutia YD. Carbidopa is an activator of aryl hydrocarbon receptor with potential for cancer therapy. Biochemical Journal 2017;474:3391-402. [DOI: 10.1042/bcj20170583] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
61 Lu ZN, Tian B, Guo XL. Repositioning of proton pump inhibitors in cancer therapy. Cancer Chemother Pharmacol 2017;80:925-37. [PMID: 28861639 DOI: 10.1007/s00280-017-3426-2] [Cited by in Crossref: 37] [Cited by in F6Publishing: 43] [Article Influence: 7.4] [Reference Citation Analysis]
62 Kolluri SK, Jin UH, Safe S. Role of the aryl hydrocarbon receptor in carcinogenesis and potential as an anti-cancer drug target. Arch Toxicol 2017;91:2497-513. [PMID: 28508231 DOI: 10.1007/s00204-017-1981-2] [Cited by in Crossref: 89] [Cited by in F6Publishing: 75] [Article Influence: 17.8] [Reference Citation Analysis]
63 Mahiout S, Lindén J, Esteban J, Sánchez-Pérez I, Sankari S, Pettersson L, Håkansson H, Pohjanvirta R. Toxicological characterisation of two novel selective aryl hydrocarbon receptor modulators in Sprague-Dawley rats. Toxicol Appl Pharmacol 2017;326:54-65. [PMID: 28433708 DOI: 10.1016/j.taap.2017.04.020] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 3.6] [Reference Citation Analysis]
64 Tsai CH, Li CH, Cheng YW, Lee CC, Liao PL, Lin CH, Huang SH, Kang JJ. The inhibition of lung cancer cell migration by AhR-regulated autophagy. Sci Rep 2017;7:41927. [PMID: 28195146 DOI: 10.1038/srep41927] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 4.8] [Reference Citation Analysis]
65 Shrestha AK, Patel A, Menon RT, Jiang W, Wang L, Moorthy B, Shivanna B. Leflunomide induces NAD(P)H quinone dehydrogenase 1 enzyme via the aryl hydrocarbon receptor in neonatal mice. Biochem Biophys Res Commun 2017;485:195-200. [PMID: 28192119 DOI: 10.1016/j.bbrc.2017.02.051] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
66 Ehrlich AK, Kerkvliet NI. Is chronic AhR activation by rapidly metabolized ligands safe for the treatment of immune-mediated diseases? Curr Opin Toxicol 2017;2:72-8. [PMID: 28944315 DOI: 10.1016/j.cotox.2017.01.007] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
67 Safe S, Cheng Y, Jin UH. The Aryl Hydrocarbon Receptor (AhR) as a Drug Target for Cancer Chemotherapy. Curr Opin Toxicol 2017;2:24-9. [PMID: 28459113 DOI: 10.1016/j.cotox.2017.01.012] [Cited by in Crossref: 53] [Cited by in F6Publishing: 49] [Article Influence: 10.6] [Reference Citation Analysis]
68 Ide H, Lu Y, Yu J, Noguchi T, Kanayama M, Muto S, Yamaguchi R, Kawato S, Horie S. Aryl hydrocarbon receptor signaling involved in the invasiveness of LNCaP cells. Human Cell 2017;30:133-9. [DOI: 10.1007/s13577-016-0158-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 2.6] [Reference Citation Analysis]
69 Spugnini E, Fais S. Proton pump inhibition and cancer therapeutics: A specific tumor targeting or it is a phenomenon secondary to a systemic buffering? Semin Cancer Biol 2017;43:111-8. [PMID: 28088584 DOI: 10.1016/j.semcancer.2017.01.003] [Cited by in Crossref: 37] [Cited by in F6Publishing: 40] [Article Influence: 7.4] [Reference Citation Analysis]
70 Bock KW. From dioxin toxicity to putative physiologic functions of the human Ah receptor in homeostasis of stem/progenitor cells. Biochemical Pharmacology 2017;123:1-7. [DOI: 10.1016/j.bcp.2016.06.015] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
71 Koltai T. Cancer: fundamentals behind pH targeting and the double-edged approach. Onco Targets Ther 2016;9:6343-60. [PMID: 27799782 DOI: 10.2147/OTT.S115438] [Cited by in Crossref: 59] [Cited by in F6Publishing: 63] [Article Influence: 9.8] [Reference Citation Analysis]
72 Patel A, Zhang S, Shrestha AK, Maturu P, Moorthy B, Shivanna B. Omeprazole induces heme oxygenase-1 in fetal human pulmonary microvascular endothelial cells via hydrogen peroxide-independent Nrf2 signaling pathway. Toxicol Appl Pharmacol 2016;311:26-33. [PMID: 27725188 DOI: 10.1016/j.taap.2016.10.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
73 Novikov O, Wang Z, Stanford EA, Parks AJ, Ramirez-Cardenas A, Landesman E, Laklouk I, Sarita-Reyes C, Gusenleitner D, Li A, Monti S, Manteiga S, Lee K, Sherr DH. An Aryl Hydrocarbon Receptor-Mediated Amplification Loop That Enforces Cell Migration in ER-/PR-/Her2- Human Breast Cancer Cells. Mol Pharmacol 2016;90:674-88. [PMID: 27573671 DOI: 10.1124/mol.116.105361] [Cited by in Crossref: 88] [Cited by in F6Publishing: 92] [Article Influence: 14.7] [Reference Citation Analysis]
74 Vila-Leahey A, Oldford SA, Marignani PA, Wang J, Haidl ID, Marshall JS. Ranitidine modifies myeloid cell populations and inhibits breast tumor development and spread in mice. Oncoimmunology 2016;5:e1151591. [PMID: 27622015 DOI: 10.1080/2162402X.2016.1151591] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
75 Joiakim A, Mathieu PA, Shelp C, Boerner J, Reiners JJ. Epidermal Growth Factor Receptor Kinase Inhibitors Synergize with TCDD to Induce CYP1A1/1A2 in Human Breast Epithelial MCF10A Cells. Drug Metabolism and Disposition 2016;44:665-71. [DOI: 10.1124/dmd.115.066274] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
76 Huang CR, Lee CT, Chang KY, Chang WC, Liu YW, Lee JC, Chen BK. Down-regulation of ARNT promotes cancer metastasis by activating the fibronectin/integrin β1/FAK axis. Oncotarget 2015;6:11530-46. [PMID: 25839165 DOI: 10.18632/oncotarget.3448] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 4.7] [Reference Citation Analysis]
77 Justiniano R, Wondrak GT. The Aryl Hydrocarbon Receptor (AhR) as an Environmental Stress Sensor and Regulator of Skin Barrier Function: Molecular Mechanisms and Therapeutic Opportunities. Skin Stress Response Pathways 2016. [DOI: 10.1007/978-3-319-43157-4_16] [Reference Citation Analysis]
78 Goswami SK, Inceoglu B, Yang J, Wan D, Kodani SD, da Silva CA, Morisseau C, Hammock BD. Omeprazole increases the efficacy of a soluble epoxide hydrolase inhibitor in a PGE₂ induced pain model. Toxicol Appl Pharmacol 2015;289:419-27. [PMID: 26522832 DOI: 10.1016/j.taap.2015.10.018] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
79 Zhang S, Patel A, Moorthy B, Shivanna B. Omeprazole induces NAD(P)H quinone oxidoreductase 1 via aryl hydrocarbon receptor-independent mechanisms: Role of the transcription factor nuclear factor erythroid 2-related factor 2. Biochem Biophys Res Commun 2015;467:282-7. [PMID: 26441083 DOI: 10.1016/j.bbrc.2015.09.173] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
80 Patel A, Zhang S, Paramahamsa M, Jiang W, Wang L, Moorthy B, Shivanna B. Leflunomide Induces Pulmonary and Hepatic CYP1A Enzymes via Aryl Hydrocarbon Receptor. Drug Metab Dispos 2015;43:1966-70. [PMID: 26417045 DOI: 10.1124/dmd.115.066084] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
81 Hanieh H. Aryl hydrocarbon receptor-microRNA-212/132 axis in human breast cancer suppresses metastasis by targeting SOX4. Mol Cancer 2015;14:172. [PMID: 26377202 DOI: 10.1186/s12943-015-0443-9] [Cited by in Crossref: 53] [Cited by in F6Publishing: 54] [Article Influence: 7.6] [Reference Citation Analysis]
82 Wang BY, Zhang J, Wang JL, Sun S, Wang ZH, Wang LP, Zhang QL, Lv FF, Cao EY, Shao ZM, Fais S, Hu XC. Intermittent high dose proton pump inhibitor enhances the antitumor effects of chemotherapy in metastatic breast cancer. J Exp Clin Cancer Res 2015;34:85. [PMID: 26297142 DOI: 10.1186/s13046-015-0194-x] [Cited by in Crossref: 103] [Cited by in F6Publishing: 109] [Article Influence: 14.7] [Reference Citation Analysis]
83 Tian J, Feng Y, Fu H, Xie HQ, Jiang JX, Zhao B. The Aryl Hydrocarbon Receptor: A Key Bridging Molecule of External and Internal Chemical Signals. Environ Sci Technol. 2015;49:9518-9531. [PMID: 26079192 DOI: 10.1021/acs.est.5b00385] [Cited by in Crossref: 70] [Cited by in F6Publishing: 63] [Article Influence: 10.0] [Reference Citation Analysis]
84 Jin UH, Kim SB, Safe S. Omeprazole Inhibits Pancreatic Cancer Cell Invasion through a Nongenomic Aryl Hydrocarbon Receptor Pathway. Chem Res Toxicol 2015;28:907-18. [PMID: 25826687 DOI: 10.1021/tx5005198] [Cited by in Crossref: 50] [Cited by in F6Publishing: 45] [Article Influence: 7.1] [Reference Citation Analysis]
85 Pombo M, Lamé MW, Walker NJ, Huynh DH, Tablin F. TCDD and omeprazole prime platelets through the aryl hydrocarbon receptor (AhR) non-genomic pathway. Toxicol Lett 2015;235:28-36. [PMID: 25797602 DOI: 10.1016/j.toxlet.2015.03.005] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
86 Murray IA, Patterson AD, Perdew GH. Aryl hydrocarbon receptor ligands in cancer: friend and foe. Nat Rev Cancer 2014;14:801-14. [PMID: 25568920 DOI: 10.1038/nrc3846] [Cited by in Crossref: 495] [Cited by in F6Publishing: 510] [Article Influence: 70.7] [Reference Citation Analysis]
87 Elbaz M, Nasser MW, Ravi J, Wani NA, Ahirwar DK, Zhao H, Oghumu S, Satoskar AR, Shilo K, Carson WE 3rd, Ganju RK. Modulation of the tumor microenvironment and inhibition of EGF/EGFR pathway: novel anti-tumor mechanisms of Cannabidiol in breast cancer. Mol Oncol 2015;9:906-19. [PMID: 25660577 DOI: 10.1016/j.molonc.2014.12.010] [Cited by in Crossref: 111] [Cited by in F6Publishing: 106] [Article Influence: 15.9] [Reference Citation Analysis]